CELC MEXC RealStocks
Own real CELC shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-19 02:53:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Celcuity Inc. (CELC) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $55.53, with a market capitalization of $2.96B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $53.54 to $151.02. This page covers its latest market performance, valuation, price trends and company information.
$2.96B | |
$57.62 | |
$58.25 | |
$55.53 | |
$58.01 | |
781.77K | |
1.24M | |
-- | |
$151.02 | |
$53.54 | |
-- | |
2026-09-30 |
Celcuity Inc. (CELC) last closed at $55.53 as of 2026-11-19 00:59:00, down 4.24% ($2.46) from the previous close of $58.01.
During the latest regular trading session, CELC traded between $55.53 and $58.25, with a volume of 781.77K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Celcuity Inc. (CELC) moved from $70.37 to $55.53, representing a decline of 21.09% ($14.84).
The stock traded between $55.53 and $72.24 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.03 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 2.0%
CELC is currently trading at $55.53, placing it 2.0% of the way from its 52-week low of $53.54 to its 52-week high of $151.02. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 155 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Celcuity Inc. (CELC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to CELC, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between CELC shares and USD.
CELC Shares to USD
1.00 CELC shares = 55.53 USD
Calculations are estimates based on the latest available price and are for reference only.